Field Test and Validation of the Multiplier Measles, Mumps, Rubella, and Varicella-Zoster Multiplexed Assay System in the Democratic Republic of the Congo by Using Dried Blood Spots.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
14 08 2019
Historique:
entrez: 16 8 2019
pubmed: 16 8 2019
medline: 7 2 2020
Statut: epublish

Résumé

Here we describe baseline validation studies and field performance of a research-use-only chemiluminescent multiplex serology panel for measles, mumps, rubella, and varicella-zoster virus used with dried blood spots in support of the 2013-2014 Democratic Republic of the Congo Demographic and Health Survey. Characterization of the panel using U.S. FDA-cleared commercial kits shows good concordance for measles, mumps, rubella, and varicella-zoster with average sensitivity across assays of 94.9% and an average specificity of 91.4%. As expected, performance versus available standards validated for plaque-reduction assays does not provide a 1:1 correspondence with international units and yet demonstrates excellent linearity (average Hill's slope = 1.02) and ∼4 logs of dynamic range. In addition, for the four assays, the multiplexed format allowed for inclusion of three positive and two negative controls for each sample. A prototype Dynex Multiplier chemiluminescent automated immunoassay instrument with a charge-coupled device camera provided a rugged and robust processing and data acquisition platform. Performance of a multiplex instrument for serological testing in a substantially resource-limited environment shows excellent reproducibility, minimal cross-reactivity, and a clear discrimination between specific assays and should be considered a viable option for future serosurveys.

Identifiants

pubmed: 31413172
pii: 4/4/e00112-19
doi: 10.1128/mSphere.00112-19
pmc: PMC6695516
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 Higgins et al.

Références

Epidemiol Infect. 1998 Dec;121(3):637-43
pubmed: 10030714
Viruses. 2016 Aug 20;8(8):
pubmed: 27556477
Clin Vaccine Immunol. 2016 Jul 05;23(7):546-54
pubmed: 27053629
BMC Public Health. 2017 Feb 1;17(1):146
pubmed: 28143602
Pediatr Infect Dis J. 2008 Aug;27(8):724-30
pubmed: 18600190
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27852634
Nat Rev Microbiol. 2006 Dec;4(12 Suppl):S20-32
pubmed: 17366684
Am J Transplant. 2013 Nov;13(11):3050-1
pubmed: 24103158
Jpn J Infect Dis. 2016 Sep 21;69(5):435-8
pubmed: 26567830
Methods. 2006 Apr;38(4):317-23
pubmed: 16481199
Pediatr Infect Dis J. 2018 Jan;37(1):28-34
pubmed: 28746265
Pediatr Infect Dis J. 2018 Feb;37(2):138-143
pubmed: 28834954
Vaccine. 2002 Aug 19;20(25-26):3130-6
pubmed: 12163264
Am J Transplant. 2013 Jul;13(7):1859-70
pubmed: 23763485
Clin Vaccine Immunol. 2011 Sep;18(9):1524-6
pubmed: 21795463
Biodemography Soc Biol. 2014;60(1):38-48
pubmed: 24784986
Pediatr Infect Dis J. 2017 May;36(5):462-466
pubmed: 28002360
J Med Virol. 2015 Sep;87(9):1491-9
pubmed: 25988945
Epidemiol Infect. 2017 Jan;145(2):236-244
pubmed: 27780480
J Virol Methods. 2006 Oct;137(1):140-9
pubmed: 16860401
Bull World Health Organ. 2016 Nov 1;94(11):794-805B
pubmed: 27821882
Trop Med Int Health. 2016 Sep;21(9):1086-98
pubmed: 27300255
Science. 2007 Nov 16;318(5853):1074-5
pubmed: 18006727
Vaccine. 2005 Jan 11;23(8):1079-84
pubmed: 15620482
Vaccine. 2009 Nov 5;27(47):6504-11
pubmed: 19665608
Mem Inst Oswaldo Cruz. 2017 Jun;112(6):428-436
pubmed: 28591403
PLoS One. 2016 Mar 02;11(3):e0149970
pubmed: 26934372
J Nutr. 2001 May;131(5):1631S-6S
pubmed: 11340130
Vaccine. 2018 Jan 25;36(4):587-593
pubmed: 29248265

Auteurs

Stephen G Higgins (SG)

Dynex Technologies Inc., Chantilly, Virginia, USA shhiggins@yahoo.com nhoff84@ucla.edu.

Nicole A Hoff (NA)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA shhiggins@yahoo.com nhoff84@ucla.edu.

Adva Gadoth (A)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA.

Andrew Fusellier (A)

Dynex Technologies Inc., Chantilly, Virginia, USA.

Patrick Mukadi (P)

National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.
Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Vivian Alfonso (V)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA.

Christina Randall (C)

Dynex Technologies Inc., Chantilly, Virginia, USA.

Hayley Ashbaugh (H)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA.

Melanie Poncheri (M)

Dynex Technologies Inc., Chantilly, Virginia, USA.

Reena H Doshi (RH)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA.

Sue Gerber (S)

Bill and Melinda Gates Foundation, Seattle, Washington, USA.

Roger Budd (R)

Dynex Technologies Inc., Chantilly, Virginia, USA.

Robert Wolfert (R)

Dynex Technologies Inc., Chantilly, Virginia, USA.

Russell Williams (R)

UCLA-DRC Research Program, Kinshasa, Democratic Republic of the Congo.

Emile Okitolonda-Wemakoy (E)

Kinshasa School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo.

Jean-Jacque Muyembe-Tamfum (JJ)

National Institute of Biomedical Research (INRB), Kinshasa, Democratic Republic of the Congo.

Anne W Rimoin (AW)

Department of Epidemiology, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH